Overview

TOPICAL INSULIN FOR GLAUCOMA, Phase 1

Status:
Not yet recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

Phase:

Phase 1

Details

Lead Sponsor:

Stanford University

Treatments:

Insulin
Insulin, Globin Zinc